Yannick De Vlaeminck
Overview
Explore the profile of Yannick De Vlaeminck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meeus F, Funeh C, Awad R, Zeven K, Autaers D, De Becker A, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39562005
Background: Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of...
2.
Hanssens H, Meeus F, Gesquiere E, Puttemans J, De Vlaeminck Y, de Veirman K, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38891821
CAR-T cell therapy is at the forefront of next-generation multiple myeloma (MM) management, with two B-cell maturation antigen (BCMA)-targeted products recently approved. However, these products are incapable of breaking the...
3.
Hanssens H, Meeus F, De Vlaeminck Y, Lecocq Q, Puttemans J, Debie P, et al.
Front Immunol
. 2024 May;
15:1389018.
PMID: 38720898
Introduction: Multiple myeloma (MM) remains incurable, despite the advent of chimeric antigen receptor (CAR)-T cell therapy. This unfulfilled potential can be attributed to two untackled issues: the lack of suitable...
4.
Van Campenhout R, Sanz-Serrano J, Cooreman A, De Vlaeminck Y, Breckpot K, Kadam P, et al.
Methods Mol Biol
. 2024 Apr;
2801:75-85.
PMID: 38578414
Connexin proteins are the building blocks of gap junctions and connexin hemichannels. Both provide a pathway for cellular communication. Gap junctions support intercellular communication mechanisms and regulate homeostasis. In contrast,...
5.
Awad R, De Vlaeminck Y, Meeus F, Ertveldt T, Zeven K, Ceuppens H, et al.
Sci Rep
. 2023 Nov;
13(1):18995.
PMID: 37923822
Blockade of the immune checkpoint axis consisting of programmed death-1 (PD-1) and its ligand PD-L1 alleviates the functional inhibition of tumor-infiltrating lymphoid cells yet weakly induces their expansion. Exogenous cytokines...
6.
Ertveldt T, Meulewaeter S, De Vlaeminck Y, Olarte O, Broos K, Van Calenbergh S, et al.
Theranostics
. 2023 Nov;
13(15):5483-5500.
PMID: 37908728
Although promising responses are obtained in patients treated with immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1) and its receptor programmed death-1 (PD-1), only a fraction of patients benefits...
7.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, et al.
J Nucl Med
. 2023 Apr;
64(5):751-758.
PMID: 37055223
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions...
8.
Awad R, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, et al.
Int Rev Cell Mol Biol
. 2022 Jul;
369:143-199.
PMID: 35777863
Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled targeted therapies to selectively target cancer...
9.
De Beck L, Awad R, Basso V, Casares N, De Ridder K, De Vlaeminck Y, et al.
Front Immunol
. 2022 May;
13:799636.
PMID: 35634329
Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical...
10.
Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, et al.
Mol Cancer Ther
. 2022 May;
21(7):1136-1148.
PMID: 35499391
Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 (177Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT with 177Lu labeled...